Post Profile






FDA proposes drug development guidance for rare pediatric diseases

(Reuters) - The U.S. Food and Drug Administration issued a draft guidance on Wednesday to simplify the procedure of developing drugs for rare pediatric disorders, such as Gaucher's disease, by eliminating the need for certain trials and minimizing patient enrollment.
read more

share

Related Posts


U.S. FDA approves Biomarin's Batten disease drug

Health : Reuters: Health

(Reuters) - The U.S. Food and Drug Administration said on Thursday it had approved Biomarin Pharmaceutical Inc's drug to treat a type of Batten disease, an extremely rare disorder that mainly impacts the nervous system.

Low-Dose Treatment with Interleukin-2 Across Multiple Studies Shows Benefits in Chronic Graft-Versus-Host Disease

Health : Newswise Medical News

Daily low doses of the immune signaling protein interleukin-2 (IL-2) can safely benefit patients who develop chronic graft-versus-host disease following stem cell transplants, including particular benefit in pediatric patients in on...

FDA outlines plan to speed rare disease drug designation

Health : Reuters: Health

WASHINGTON (Reuters) - The U.S. Food and Drug Administration plans to reorganize its drug review staff and create a SWAT team to eliminate a backlog of requests for rare disease drug designation, it said on Thursday.

Drug for Rare Blood Disorder Developed at Penn Receives Orphan Drug Status from the FDA

Health : Newswise Medical News

A Penn Medicine-developed drug has received orphan status from the Food and Drug Administration (FDA) this month for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening disease that causes anemia due...

FDA Approves Therapy To Treat Gaucher Disease

Health : Medical News Today

The U.S. Food and Drug Administration has approved velaglucerase alfa for injection (VPRIV) to treat children and adults with a form of the rare genetic disorder Gaucher disease. Gaucher disease occurs in people who do not produce e...

Comments


Copyright © 2016 Regator, LLC